

CONTACT - Media:

Amsterdam +31.20.721.4488
Lisbon +351.210.600.614

Brussels +32.2.620.15.50
Paris +33.1.70.48.24.45

CONTACT - Investor Relations:

+33.1.70.48.24.17

BIOM'UP LISTS ON EURONEXT PARIS TO FINANCE ITS DEVELOPMENT**€38.1 million raised; market capitalisation approximately €113.4 million**

Paris – 13 October 2017 – Biom'Up, a specialist in hemostatic products used in surgery, listed today in Compartment C of Euronext Paris, joining the community of over 330 small and mid-sized tech companies – including more than 80 operating in life sciences – on Euronext's pan-European markets.

Thanks to a world-renowned medical team and their scientific expertise in the field of biopolymers, Biom'Up has developed HEMOBLAST™ Bellows, a world-class hemostatic product that aims to control bleeding during surgical operations (e.g., spine, heart, orthopedic or general surgeries). Bleeding leads to complications during surgery and lengthens the surgical procedure. Therefore hemostatic products are crucial in surgical operations that present a significant risk of bleeding. Today these products represent a global growth market estimated at 2 billion dollars. The US and European markets already established (e.g., spine and cardiovascular surgeries) represent an opportunity of 1.2 billion dollars.

HEMOBLAST™ Bellows obtained the CE Mark in December 2016, and the PMA (Pre-Market Approval) application was submitted to the FDA (Food & Drug Administration) in July 2017 with a view to obtaining marketing approval in the United States in mid-2018.

Biom'Up (ticker code BUP) was listed through the admission to trading on 13 October 2017 of 10,802,907 shares including 3,631,579 new shares issued as part of a Global Offering¹ including the full exercise of the extension option and excluding the potential exercise of the over-allotment option.

The offering price was set at €10.5 per share. Market capitalisation was around €113.4 million on the day of listing, and the IPO raised a total of €38.1 million.

At the listing ceremony, Etienne Binant, Chief Executive Officer of Biom'Up, said: *"I am very pleased to announce today the success of our IPO on the regulated market of Euronext in Paris. I welcome the new French, European and American shareholders, and thank them for their trust. This operation was made possible by the empowerment and the financial investment of the management team (Bill Spotnitz, João-*

¹ The Global Offering was made up of a Public Offering that included an Open Price Offer (OPO) in France and a Global Placement in France and other countries, primarily with institutional investors.

Paulo Alves and Jan Ohrstrom), as well as the support of the historical shareholders. We are now in the most favourable conditions to deploy our range of hemostatic products – especially HEMOBLAST™ Bellows – in Europe and North America. We will maintain our R&D investments and conduct new clinical studies to gain access to new surgical indications for the benefit of patients and clinicians.”



CONTACTS -

Euronext

Pauline Bucaille (Europe):

+33 1 70 48 24 41; pbucaille@euronext.com

Aïchata Tandjigora (Paris):

+33 1 70 48 24 43; atandjigora@euronext.com

About Biom'Up

Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom'Up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life. Its flagship product, HEMOBLAST™ Bellows, is a unique hemostatic solution, ready to use (no preparation time needed, no need to mix, no heat required), usable once or several times during the surgery. Developed by a world-renowned scientific team, HEMOBLAST™ Bellows has obtained positive results for all the primary and secondary endpoints of Phase III of its pivotal study involving 412 patients in the United States. HEMOBLAST™ Bellows obtained its CE Mark in December 2016, and its PMA (Pre-Market Approval) application was submitted to the FDA (Food & Drug Administration) in July 2017 with a view to obtaining marketing approval in the United States in mid-2018. Since its creation, Biom'Up has benefited from the support of prominent European investors such as Bpifrance, Innobio, GIMV, Lundbeckfond, Mérieu XParticipation, SHAM and ACG, as well as all the Company's managers, who have invested €2 million in equity.

About Euronext

Euronext is the leading pan-European exchange in the Eurozone with nearly 1,300 listed issuers worth close to €3.6 trillion in market capitalisation as of end September 2017, an unmatched blue chip franchise consisting of 24 issuers in the Morningstar® Eurozone 50 IndexSM and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM (formerly known as Alternext) and Euronext AccessTM (formerly known as the Free Market). For the latest news, find us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided "as is" without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial

products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2017, Euronext N.V. - All rights reserved.